69 results
PRE 14A
ALBT
Avalon GloboCare Corp
29 Aug 23
Preliminary proxy
4:55pm
American: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology. Dr. Jin also acts as a senior translational
8-K
EX-99.1
ALBT
Avalon GloboCare Corp
27 Apr 23
Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022
4:26pm
™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates
8-K
EX-99.1
44d03evq uc2
14 Dec 22
Entry into a Material Definitive Agreement
9:18am
DEFA14A
spke2lqzm2x
12 Dec 22
Additional proxy soliciting materials
10:41am
8-K
EX-99.1
if0m6b e3
8 Nov 22
Entry into a Material Definitive Agreement
9:15am
8-K
EX-99.1
6lfd8
4 Jan 22
Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
9:05am
8-K
EX-99.1
bemhn5e6mja h4knfc
22 Dec 21
Entry into a Material Definitive Agreement
11:17am